Highest-materiality recent filing
Phio Pharma Q1 net loss $4.0M; PH-762 Phase 1b trial complete with favorable safety
Cash and cash equivalents $17M at March 31, 2026; 2025 equity financings netted ~$23.7M, extending cash runway into H1 2027.
Phio Pharmaceuticals enters ATM offering agreement with H.C. Wainwright for up to $6.36M
Agreement allows sale of up to $6,360,000 of common stock via H.C. Wainwright as sales agent on an at-the-market basis.
Phio signs cGMP manufacturing deal; PH-762 Phase 1b shows 85% pathological response
Entered cGMP drug product manufacturing agreement with U.S. manufacturer for clinical and commercial supply of PH-762.
Net loss of $8.7M ($1.45 EPS) for 2025 vs $7.2M ($9.08 EPS) in 2024; R&D expenses up 27%.
Phio Pharmaceuticals amends CEO Bitterman's contract: severance to 12 months, bonus target to 50%
CEO Robert J. Bitterman's severance increased to 12 months base salary on termination without cause or for good reason.
No serious adverse events or dose-limiting toxicities across all 22 patients in five dose cohorts.
Phio reports 70% ORR in cSCC from PH-762 trial; 10 of 14 responders had 100% clearance
22 cutaneous carcinoma patients treated across 5 dose cohorts; no dose-limiting toxicities reported.
Phio Pharma gets FDA acceptance of PH-762 nonclinical study design; tox study Q1 2026
FDA accepted nonclinical protocol study design for PH-762; toxicology study to begin Q1 2026.
Phio completes enrollment in Phase 1b trial of PH-762; positive pathologic responses
18 patients treated across 5 dose cohorts; 16 with cSCC, 1 Merkel cell, 1 melanoma.
Phio Pharma Q3 net loss $2.4M; PH-762 trial 100% tumor clearance at max dose
Net loss $2.4M for Q3 2025 vs $1.5M in Q3 2024; R&D expenses $1.2M, G&A $1.3M.
Phio raises ~$13.4M via warrant exercise inducement; issues new warrants for 11.3M shares
Entered inducement agreements for exercise of 5,663,182 existing warrants at reduced prices; gross proceeds ~$13.4M.
Phio Pharma: INTASYL PH-762 shows 100% tumor clearance in one cSCC patient; SMC clearance safe
100% pathologic complete response in 1 of 3 cSCC patients at Day 36 in final dose cohort; >90% clearance in second, >50% in third.
Director Robert Ferrara resigns; David Deming appointed Lead Independent Director
Robert Ferrara resigned effective Oct 31, 2025; no disagreement cited.
All six director nominees elected with 84-94% of votes cast; 1,828,465 broker non-votes.
Phio advances Phase 1b skin cancer trial to 5th cohort; presents at conference
Patients are now being treated in the 5th cohort of the ongoing Phase 1b clinical trial for skin cancer (PH-762).
Phio Pharma Q2 net loss $2.2M; advances PH-762 Phase 1b to 5th cohort
Net loss $2.2M for Q2 2025 vs $1.8M in Q2 2024; cash $10.8M at June 30, 2025.
Phio Pharma receives ~$2.5M from warrant exercise, issues new warrants
Gross proceeds ~$2.5M from exercise of 928,596 warrants at $2.00 and $2.485 per share.
Phio reports complete response in cSCC and manufacturing agreement for PH-762
Entered into comprehensive drug substance development agreement with U.S. manufacturer for PH-762.
Phio sets 2025 annual meeting for Sept 11; new proposal deadlines
Annual meeting on Sept 11, 2025; record date July 18, 2025.
Phio Pharmaceuticals gets SMC nod to advance PH-762 skin cancer trial to fifth cohort
Safety Monitoring Committee recommends dose escalation to fifth (final) cohort in Phase 1b trial of INTASYL PH-762.
Phio Pharmaceuticals appoints Lisa Carson as CFO/PAO; Infarinato shifts to VP Strategic Development
Lisa Carson named VP Finance and Administration and designated principal financial and accounting officer, effective June 6, 2025.
Also effective June 6, 2025, Mr. Infarinato, who was previously the Company’s Chief Financial Officer, now serves as VP, Strategic Development of the Company.
designated Lisa Carson, VP, Finance and Administration of the Company, as the Company’s principal financial officer and principal accounting officer, effective as of June 6, 2025.
Max materiality 0.90 · Median 0.65 · Most common event other_material